Alnylam Pharmaceuticals (NASDAQ:ALNY) Announces Quarterly Earnings Results, Misses Estimates By $0.61 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.61), Briefing.com reports. The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 1.36% and a return on equity of 26.61%. The business’s quarterly revenue was up 84.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.65) EPS.

Here are the key takeaways from Alnylam Pharmaceuticals’ conference call:

• GAAP profitability: Alnylam achieved GAAP profitability for full‑year 2025 and reported nearly $3.0 billion in combined net product revenues (81% YoY), with the AMVUTTRA ATTR‑CM launch cited as the primary driver.
• 2026 guidance and 2030 goals: The company reiterated 2026 combined product sales guidance of $4.9–$5.3 billion (TTR $4.4–$4.7B) and launched “Alnylam 2030” targets aiming for global TTR leadership, >25% revenue CAGR to 2030 and ~30% non‑GAAP operating margin through 2030.
• AMVUTTRA launch dynamics: Early U.S. uptake is strong—approaching parity with tafamidis in new starts and >90% payer first‑line coverage—however management flagged expected Q1 2026 headwinds from German pricing adjustments, seasonality and a mid‑single‑digit net price decline assumption.
• Pipeline and platform progress: Alnylam initiated three Phase‑3 trials (ZENITH for zilebesiran; TRITON‑CM and TRITON‑PN for nucresiran), added four new Alnylam clinical programs (e.g., ACVR1C and MAPT) and launched the Syrelis enzymatic ligation manufacturing platform to expand capacity and lower COGS.
• Near‑term financial headwinds: Gross margin declined to 77% in 2025 due to higher royalties (Sanofi), 2026 collaboration/royalty revenue guidance is down (no repeat of the $300M milestone), and the company anticipates continued net price pressure in the U.S.

Alnylam Pharmaceuticals Stock Down 4.3%

Shares of NASDAQ:ALNY opened at $308.48 on Friday. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $495.55. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The stock has a market cap of $40.75 billion, a P/E ratio of 1,285.33 and a beta of 0.35. The firm has a fifty day moving average price of $377.85 and a 200 day moving average price of $424.10.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Record revenue and first-time profitability: Alnylam reported a breakout year with nearly $3B in net product revenues (about +81% YoY) and the company turned profitable, a major milestone that supports long-term valuation upside. Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
• Positive Sentiment: Strong longer-term growth targets and AMVUTTRA momentum: Management reiterated ambitious growth plans (targeting a high revenue CAGR through 2030) with AMVUTTRA the primary growth engine, which underpins buy-side bullishness on durable top-line expansion. Alnylam targets 25% revenue CAGR through 2030 amid AMVUTTRA launch momentum and pipeline expansion
• Positive Sentiment: Analysts largely remain constructive: Some street analysts (e.g., TD Cowen) kept Buy ratings after the print, and others trimmed price targets modestly but stayed positive, signaling continued institutional support. Alnylam Pharmaceuticals: Amvuttra-Driven Profitability Inflection Supports Long-Term Growth and Buy Rating
• Neutral Sentiment: FY‑2026 revenue guidance is a range: Management gave a revenue range for FY‑2026 (roughly $5.3–$5.8B), which is near consensus — reassuring for some investors but broad enough to leave room for upside or downside depending on AMVUTTRA rollout. Here’s What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings
• Negative Sentiment: AMVUTTRA ATTR revenue and EPS reporting created mixed reads: Several outlets flagged AMVUTTRA ATTR revenue came in below some expectations and there are differing attendees’ takes on EPS (adjusted vs. GAAP), which spurred selling pressure as investors reassessed near-term momentum. Alnylam turns profitable even as Amvuttra ATTR revenue disappoints in Q4
• Negative Sentiment: Execution and scaling risk called out by company: Alnylam disclosed material execution risks tied to scaling global operations for AMVUTTRA and broader 2030 ambitions — a reminder that operational hurdles or higher costs could pressure margins or growth if rollout problems emerge. Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total transaction of $848,055.70. Following the transaction, the executive vice president owned 21,264 shares of the company’s stock, valued at $7,874,697.12. This trade represents a 9.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Pushkal Garg sold 1,510 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the sale, the executive vice president directly owned 22,511 shares of the company’s stock, valued at approximately $8,168,566.57. This represents a 6.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 31,305 shares of company stock valued at $12,459,785. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently bought and sold shares of ALNY. Summit Financial LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $579,000. Quadrant Capital Group LLC lifted its position in Alnylam Pharmaceuticals by 11.2% in the fourth quarter. Quadrant Capital Group LLC now owns 615 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 62 shares during the period. DRW Securities LLC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $812,000. MetLife Investment Management LLC increased its position in Alnylam Pharmaceuticals by 2.4% during the 4th quarter. MetLife Investment Management LLC now owns 8,187 shares of the biopharmaceutical company’s stock worth $3,256,000 after purchasing an additional 195 shares during the period. Finally, Cibc World Markets Corp acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $4,360,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday. Truist Financial dropped their target price on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Jefferies Financial Group decreased their price target on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th. Wells Fargo & Company dropped their price objective on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 20th. Finally, Needham & Company LLC decreased their target price on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday. Twenty-two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $476.34.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.